<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
  • Menu
  • crown-logo-symbol-1-400x551

Find it Quickly

Get Started

Select the option that best describes what you are looking for

  • Services
  • Models
  • Scientific Information

Search Here For Services

Click Here to Start Over

Search Here For Models

Click Here to Start Over

Search Here For Scientific Information

Click Here to Start Over

In Vitro

Boost oncology drug discovery with XenoBase®, featuring the largest cell line selection and exclusive 3D organoid models. Benefit from OrganoidXplore™ and OmniScreen™ for rapid, in-depth analysis.

Learn More

In Vivo

Enhance drug development with our validated in vivo models, in vitro/ex vivo assays, and in silico modeling. Tailored solutions to optimize your candidates.

Learn More

Tissue

Experience ISO-certified biobanking quality. Access top biospecimens from a global clinical network, annotated by experts for precise research.

Learn More

Biomarkers and Bioanalysis

Leverage our global labs and 150+ scientists for fast, tailored project execution. Benefit from our expertise, cutting-edge tech, and validated workflows for reliable data outcomes.

Learn More

Data Science and Bioinformatics

Harness your data and discover biomarkers with our top bioinformatics expertise. Maximize data value and gain critical insights to accelerate drug discovery and elevate projects.

Learn More

KRAS

Accelerate innovative cancer treatments with our advanced models and precise drug screening for KRAS mutations, efficiently turning insights into clinical breakthroughs.

Learn More

EGFR

Advance translational pharmacology with our diverse pre-clinical models, robust assays, and data science-driven biomarker analysis, multi-omics, and spatial biology.

Learn More

Drug Resistance

Our suite integrates preclinical solutions, bioanalytical read-outs, and multi-omics to uncover drug resistance markers and expedite discovery with our unique four-step strategy.

Learn More

Patient Tissue

Enhance treatments with our human tumor and mouse models, including xenografts and organoids, for accurate cancer biology representation.

Learn More

Target to Lead Selection for ADCs and Biologics

Journey through the drug discovery pipeline from target discovery to in vivo pharmacology. Take advantage of the Largest biobank of patient-derived models, Model development capabilities, Cell-based assays for Screening ADCs, and advanced downstream analysis.

Learn More

Bioinformatics

Apply the most appropriate in silico framework to your pharmacology data or historical datasets to elevate your study design and analysis, and to improve your chances of clinical success.

Learn More

Biomarker Analysis

Integrate advanced statistics into your drug development projects to gain significant biological insight into your therapeutic candidate, with our expert team of bioinformaticians.

Learn More

CRISPR/Cas9

Accelerate your discoveries with our reliable CRISPR solutions. Our global CRISPR licenses cover an integrated drug discovery platform for in vitro and in vivo efficacy studies.

Learn More

Genomics

Rely on our experienced genomics services to deliver high quality, interpretable results using highly sensitive PCR-based, real-time PCR, and NGS technologies and advanced data analytics.

Learn More

In Vitro High Content Imaging

Gain more insights into tumor growth and disease progression by leveraging our 2D and 3D fluorescence optical imaging.

Learn More

Mass Spectrometry-based Proteomics

Next-generation ion mobility mass spectrometry (MS)-based proteomics services available globally to help meet your study needs.

Learn More

Ex Vivo Patient Tissue

Gain better insight into the phenotypic response of your therapeutic candidate in organoids and ex vivo patient tissue.

Learn More

Spatial Multi-Omics Analysis

Certified CRO services with NanoString GeoMx Digital Spatial Profiling.

Learn More

Biomarker Discovery

De-risk your drug development with early identification of candidate biomarkers and utilize our biomarker discovery services to optimize clinical trial design.

Learn More

DMPK Services

Rapidly evaluate your molecule’s pharmaceutical and safety properties with our in vivo drug metabolism and pharmacokinetic (DMPK) services to select the most robust drug formulations.

Learn More

Efficacy Testing

Explore how the novel HuGEMM™ and HuCELL™ platforms can assess the efficacy of your molecule and accelerate your immuno-oncology drug discovery programs.

Learn More

Laboratory Services

Employ cutting-edge multi-omics methods to obtain accurate and comprehensive data for optimal data-based decisions.

Learn More

Pharmacology & Bioanalytical Services

Leverage our suite of structural biology services including, recombinant protein expression and protein crystallography, and target validation services including RNAi.

Learn More

Screens

Find the most appropriate screen to accelerate your drug development: discover in vivo screens with MuScreen™ and in vitro cell line screening with OmniScreen™.

Learn More

Toxicology

Carry out safety pharmacology studies as standalone assessments or embedded within our overall toxicological profiling to assess cardiovascular, metabolic and renal/urinary systems.

Learn More

Preclinical Consulting Services

Learn more about how our consulting services can help to support your journey to the clinic.

Learn More

Our Company

Global CRO in California, USA offering preclinical and translational oncology platforms with high-quality in vivo, in vitro, and ex vivo models.

Learn More

Our Purpose

Learn more about the impact we make through our scientific talent, high-quality standards, and innovation.

Learn More

Our Responsibility

We build a sustainable future by supporting employee growth, fostering leadership, and exceeding customer needs. Our values focus on innovation, social responsibility, and community well-being.

Learn More

Meet Our Leadership Team

We build a sustainable future by fostering leadership, employee growth, and exceeding customer needs with innovation and social responsibility.

Learn More

Scientific Advisory Board

Our Scientific Advisory Board of experts shapes our strategy and ensures top scientific standards in research and development.

Learn More

News & Events

Stay updated with Crown Bioscience's latest news, achievements, and announcements. Check our schedule for upcoming events and plan your visit.

Learn More

Career Opportunities

Join us for a fast-paced career addressing life science needs with innovative technologies. Thrive in a respectful, growth-focused environment.

Learn More

Scientific Publications

Access our latest scientific research and peer-reviewed articles. Discover cutting-edge findings and insights driving innovation and excellence in bioscience.

Learn More

Resources

Discover valuable insights and curated materials to support your R&D efforts. Explore the latest trends, innovations, and expertly curated content in bioscience.

Learn More

Blogs

Explore our blogs for the latest insights, research breakthroughs, and industry trends. Stay educated with expert perspectives and in-depth articles driving innovation in bioscience.

Learn More

  • Platforms
  • Target Solutions
  • Technologies
  • Service Types

CAR T Immunotherapy Revs Up for Glioblastoma

A new clinical trial in glioblastoma has been launched based on an innovative immunotherapeutic technique – the CAR T cell which can modify then harness a patient’s own T cells to fight their disease.

Immunotherapy news (including our blog) often focusses on checkpoint inhibitors like anti-PD-1 and anti-CTLA-4 antibodies, as they make important leaps forward in providing new therapies for a range of cancer patients. The immunotherapy field is obviously much larger than this, and other approaches such as therapeutic vaccines are also showing efficacy in different cancer types. Another treatment type which created a lot of news last week, is chimeric antigen receptor T cells (or CAR T cells) which, following promising preclinical results, are moving into Phase I study in glioblastoma.

What is CAR T cell treatment?

CARs are synthetic molecules which are designed to redirect patient T cells to specific antigens e.g. in cancer immunotherapy, T cells are modified to express receptors which are specific to a particular form of cancer, and which are not found on ‘normal’ tissue. When the CAR T cells are given to patients, they recognize and kill the specific cancer cells without harming other parts of the body. In cancers of the blood (such as disease of the B cells), CAR T cells have been shown to cause long-term, durable disease remission, but moving this into solid tumor therapy has been limited by the lack of targets which are found only on cancer cells.

Exciting new preclinical work published last week in Science Translational Medicine has made the move into the solid tumor world of glioblastoma, specifically for patients with the EGFRvIII mutation. This mutation is thought to be tumor-specific, and is the most common EGFR variant found in human tumors. It is seen in around 30% of glioblastoma patients, and is linked to their poor long-term survival. No current treatments for this specific cancer type can cure the disease, with median survival for people newly diagnosed with glioblastoma being less than 15 months, meaning that new therapies are urgently needed.

CAR T therapies for this specific cancer type have been described before. The new research focused on making sure the CAR T cells were highly specific, didn’t react with wild type EGFR, and were humanized to prevent human anti-mouse antibody responses. The resulting CAR T cells were then tested preclinically in xenogeneic subcutaneous and orthotopic mouse models of human EGFRvIII+ glioblastoma, with results measured by MRI and bioluminescent imaging. Single agent CAR T cells were able to eliminate the glioblastoma tumor, and an even deeper tumor regression was seen when used in combination with temozolomide, which is a current therapy to treat the disease.

The results have been positive enough to open a Phase I clinical trial with this agent, enrolling 12 patients with either recurring disease or patients with residual disease following initial surgery. Patients will have some of their T cells removed and engineered using a viral vector to be able to find cancer cells expressing EGFRvIII. These engineered cells are then infused back into the patients, to proliferate and search out the cancer cells of interest, hopefully sparing normal cells.

Crown Bioscience are excited to see more new immunotherapies and techniques moving into clinical trial, especially for cancer types that need new treatment options. Crown Bioscience support research in immune therapies with a range of immunotherapy platforms (with either murine or human immunity) in a variety of different cancer types (including brain cancer), with syngenic models (including bioluminescent and metastatic models), GEMM, MuPrime™ (the murine version of HuPrime® which is the world’s largest collection of well-characterized and validated Patient-Derived Xenograft models), HuMice™ (humanized mice produced through inoculating human hematopoietic cells into immunocompromised mice), and MiXeno™ (creating transient human immunity by mixing human peripheral blood mononucleated cells with xenograft models). We also support glioblastoma research through the use of our clinically relevant Xenograft and Patient-Derived Xenograft models available for drug discovery and translational sciences.

Contact us today at busdev@crownbio.com to discover how we can transform your immunotherapy and glioblastoma research today.


Related Posts